Carbamazepine co-treatment in Schizophrenia;Zur adjuvanten behandlung schizophrener storungen mit carbamazepin

Fortschritte der Neurologie Psychiatrie

Volumn 66, Issue 4, 1998, Pages 145-150

  Hesslinger B ^a   Klose, P ^a   Normann, C ^a   Langosch, J M ^a   Berger, M ^a   Walden, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HALOPERIDOL; NEUROLEPTIC AGENT; ANTICONVULSIVE AGENT;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME INDUCTION; HUMAN; SCHIZOPHRENIA; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERACTION; REVIEW;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; DRUG INTERACTIONS; HUMANS; SCHIZOPHRENIA;

EID: 0031920753     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995249     Document Type: Article

References (26)

1. Altamura, A. C., G. L. Tacchini, M. Maes: Haloperidol plasma "treshold" levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. European Neuropsychopharmacology Supplement (1995) 55-58
2. Arana, G. W., D. C. Goff, H. Friedman, M. Ornsteen, D. G. Greenblatt, B. Black, R. I. Shader: Does Carbamazepine-Induced Reduction of Plasma Haloperidol Levels Worsen Psychotic Symptoms? Am. J. Psychiatry 143, 5 (1986) 650-651
3. Baldessarini, R. J., B. M. Cohen, M. H. Teicher: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45 (1988) 179-191
4. Bjorndal, N., M. Bjerre, J. Gerlach, P. Kritjansen, G. Magelund, I. H. Oestruch, J. Waerens: High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 67 (1980) 17-23
5. Daniel, D. G., C. Randolph, G. Jaskiw, S. Handel, T. Williams, A. Abi-Dargham, S. Shoaf, M. Egan, A. Elkashef, S. Liboff, M. Linnoila: Coadministration of Fluvoxamine Increases Serum Concentrations of Haloperidol. J. Clin. Psychopharmacol. 14 (1994) 340 -343
6. Daniel, W., K. J. Netter: Metabolic interaction between imipramine and carbamazepine in vivo and in vitro. Arch. Pharmacol. 337 (1988) 105-110
7. Dose, M., H. M. Emrich: Carbamazepine als Adjuvans der neuroleptischen Behandlung schizophrener Psychosen. In: Müller-Oerlinghausen, B., S. Haas, K. D. Stoll (Hrsg.): Carbamazepin in der Psychiatrie. Georg Thieme Verlag, Stuttgart, New York (1989) 225-232
8. Jann, M. W., L. Ereshefsky, S. R. Saklad, D. R. Seidel, C. M. Davis, N. R. Burch, C. L. Bowden: Effects of Carbamazepine on Plasma Haloperidol Levels. J. Clin. Psychopharmacol. 5 (1985) 106-109
9. Jann, M. W., G. S. Fidone, J. M. Hernandez, S. Amrung, C. M. Davis: Clinical Implications of Increased Antipsychotic Plasma Concentrations Upon Anticonvulsant Cessation. Psychiatry Research 28 (1989) 153-159
10. Kahn, E. M., S. C. Schulz, J. M. Perel, J. E. Alexander: Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia. J. Clin. Psychopharmacol. 10/1 (1990) 54-57
11. Ketter, T. A., D. A. Flockhart, R. M. Post, K. D. Denicoff, P. J. Pazzaglia, L. B. Marangell, M. S. George, A. M. Callahan: The Emerging Role of Cytochrome P450 3A in Psychopharmacology. J. Clin. Psychopharmacol. 15 (1995) 387-398
12. Klein, E., E. Bental, B. Lerer, H. Belmaker: Carbamazepine and Haloperidol v Placebo and Haloperidol in Excited Psychoses. Arch. Gen. Psychiatry 41 (1984) 165-171
13. Kornhuber, J., A. Schultz, P. Riederer: Haloperidol concentration in human brain tissue: Effects of dosage, duration of treatment and drug-free time. Biol. Psychiatry 42 (1997) 1S-297S
14. Krämer, G., R. Besser, M. Theisohn: Interaktionen von Carbamazepin mit anderen Medikamenten. In: Krämer, G., H. C. Hopf (Hrsg.): Carbamazepin in der Neurologie. Georg Thieme Verlag, Stuttgart, New York (1987) 70-91
15. Leinonen, E., P. Lillsunde, V. Laukkanen, P. Ylitalo: Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J. Clin. Psychopharmacol. 11 (1991) 313-318
16. Nemeroff, C. B., L. DeVane, B. G. Pollock: Newer Antidepressants and the Cytochrome P450 System. Am. J. Psychiatry 153 (1996) 311-320
17. Neppe, V. M.: Carbamazepin as adjunctive treatment in nonepileptic chronic inpatients with EEC temporal lobe abnormalities. J. Clin. Psychiat. 44 (1983) 326-331
18. Nyberg, S., L. Farde, C. Halldin, M. L. Dahl, L. Bertilsson: D2 dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Am. J. Psychiatry 152 (1995) 173-178
19. Perry, P. J., D. D. Miller, S. V. Arndt, R. J. Caboret: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry 148 (1991) 231-235
20. Pupeschi, G., C. Agenet, J. C. Levron, M. H. Barges-Bertocchio: Do enzyme inducers modify haloperidol decanoate rate of release? Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 18 (1994) 1323-1332
21. Theisohn, M., M. Dose, S. Apelt, H. M. Emrich: Pharmakokinetische und pharmakodynamische Interaktionen von Haloperidol und Carbamazepin bei psychiatrischen Patienten. In: Müller-Oerlinghausen, B., S. Haas, K. D. Stoll (Hrsg.): Carbamazepin in der Psychiatrie. Georg Thieme Verlag, Stuttgart, New York (1989) 38-46
22. Van Putten, T., S. R. Marder, W. C. Wirshing, M. Aravagiri, N. Chabert: Neuroleptic Plasma Levels. Schizophrenia Bulletin 17 (1991) 197-216
23. Van Putten, T., S. R. Marder, J. Mintz, R. E. Poland: Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry 149 (1992) 500-505
24. Walden, J., B. Heßlinger: Bedeutung alter und neuer Antiepileptika in der Behandlung psychischer Erkrankungen. Fortschr. Neurol. Psychiat. 63 (1995) 320-335
25. Wilder, B. J.: Pharmacokinetics of valproate and carbamazepine. J. Clin. Psychopharmacol. 12 (1992) 64S-68S
26. Wolkin, A., J. D. Brodie, F. Barouche, J. Rotrosen, A. P. Wolf, M. Smith, J. Fowler, T. Cooper: Dopamin receptor occupancy and plasma haloperidol levels. Arch. Gen. Psychiatry 46 (1989) 482 -483